Department of Radiation Oncology, Tai Zhou Central Hospital, Tai Zhou, Zhe Jiang, 318000, China.
Department of Obstetrics and Gynecology, Tai Zhou Central Hospital, Tai Zhou, Zhe Jiang, 318000, China.
World J Surg Oncol. 2018 Jan 29;16(1):18. doi: 10.1186/s12957-017-1307-0.
The objective of this study is to analyze the treatment outcome and secondary reactions in 98 patients with stage I-III cervical carcinoma who underwent postoperative radiotherapy.
From 2006 to 2014, 98 patients with stage I-III cervical carcinoma were treated with postoperative radiotherapy. The major histological type, found in 92.86% of the patients (91 cases), was squamous cell carcinoma. Patients were staged according to the 2002 TNM guidelines. The postoperative radiotherapy methods included two-field irradiation (16 patients, 16.32%), four-field box irradiation (16 patients, 16.32%), and intensity-modulated radiotherapy (IMRT; 66 patients, 67.36%). The survival rates were represented using Kaplan-Meier curves, and prognosis analyses were performed using Cox multivariate analyses.
The 5-year overall survival and progression-free survival rates were 82.0 and 76.0%, respectively. Only one patient (1.02%) developed a grade 3 acute radiation enteritis, while grade 3 and 4 myelosuppression was noted in 17 patients (17.35%) and one patient (1.02%), respectively. Multivariate analyses showed that anemia before radiotherapy and tumor size were predictors of the OS (P = 0.008, P = 0.045) rates.
Postoperative radiotherapy for patients with risk factors of cervical cancer procured good efficacy levels with mild side effects. Anemia and tumor size were important OS predictors.
本研究旨在分析 98 例Ⅰ-Ⅲ期宫颈癌术后放疗患者的治疗效果和不良反应。
2006 年至 2014 年,对 98 例Ⅰ-Ⅲ期宫颈癌患者进行术后放疗。92.86%(91 例)的主要组织学类型为鳞状细胞癌。患者分期依据 2002 年 TNM 分期标准。术后放疗方法包括两野照射(16 例,16.32%)、四野箱照射(16 例,16.32%)和调强放疗(IMRT;66 例,67.36%)。采用 Kaplan-Meier 曲线表示生存率,采用 Cox 多因素分析进行预后分析。
5 年总生存率和无进展生存率分别为 82.0%和 76.0%。仅 1 例(1.02%)发生 3 级急性放射性肠炎,17 例(17.35%)和 1 例(1.02%)分别发生 3 级和 4 级骨髓抑制。多因素分析显示,放疗前贫血和肿瘤大小是 OS(P=0.008,P=0.045)的预测因素。
对宫颈癌高危因素患者进行术后放疗疗效较好,不良反应较轻。贫血和肿瘤大小是 OS 的重要预测因素。